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Cigarette toxicity triggers Leber’s hereditary optic
neuropathy by affecting mtDNA copy number, oxidative
phosphorylation and ROS detoxification pathways
L Giordano1, S Deceglie1, P d’Adamo2,3, ML Valentino4,5, C La Morgia4,5, F Fracasso1, M Roberti1, M Cappellari1, G Petrosillo6,
S Ciaravolo7, D Parente7, C Giordano8, A Maresca4,5, L Iommarini4,5, V Del Dotto9, AM Ghelli9, SR Salomao10, A Berezovsky10,
R Belfort Jr10, AA Sadun11, V Carelli*,4,5, P Loguercio Polosa1 and P Cantatore*,1,6
Leber’s hereditary optic neuropathy (LHON), the most frequent mitochondrial disease, is associated with mitochondrial DNA
(mtDNA) point mutations affecting Complex I subunits, usually homoplasmic. This blinding disorder is characterized by
incomplete penetrance, possibly related to several genetic modifying factors. We recently reported that increased mitochondrial
biogenesis in unaffected mutation carriers is a compensatory mechanism, which reduces penetrance. Also, environmental factors
such as cigarette smoking have been implicated as disease triggers. To investigate this issue further, we first assessed the
relationship between cigarette smoke and mtDNA copy number in blood cells from large cohorts of LHON families, finding that
smoking was significantly associated with the lowest mtDNA content in affected individuals. To unwrap the mechanism of tobacco
toxicity in LHON, we exposed fibroblasts from affected individuals, unaffected mutation carriers and controls to cigarette smoke
condensate (CSC). CSC decreased mtDNA copy number in all cells; moreover, it caused significant reduction of ATP level only in
mutated cells including carriers. This implies that the bioenergetic compensation in carriers is hampered by exposure to smoke
derivatives. We also observed that in untreated cells the level of carbonylated proteins was highest in affected individuals, whereas
the level of several detoxifying enzymes was highest in carriers. Thus, carriers are particularly successful in reactive oxygen
species (ROS) scavenging capacity. After CSC exposure, the amount of detoxifying enzymes increased in all cells, but
carbonylated proteins increased only in LHON mutant cells, mostly from affected individuals. All considered, it appears that
exposure to smoke derivatives has a more deleterious effect in affected individuals, whereas carriers are the most efficient in
mitigating ROS rather than recovering bioenergetics. Therefore, the identification of genetic modifiers that modulate LHON
penetrance must take into account also the exposure to environmental triggers such as tobacco smoke.
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Leber’s hereditary optic neuropathy (LHON) is among the most
frequent mitochondrial diseases, affecting about 1 in 35 000–
60 000 in Europe.1,2 LHON is associated in over 90% of cases
with one of three common mitochondrial DNA (mtDNA) point
mutations affecting the Complex I subunit genes ND4
(m.11778G4A), ND1 (m.3460G4A) and ND6 (m.14484
T4C), usually occurring in homoplasmic fashion3,4 (100% of
mtDNA is mutant). This maternally inherited blinding disorder is
caused by selective degeneration of retinal ganglion cells,
particularly those originating the small axons composing the
papillomacular bundle, which leads to optic atrophy.5–7 Clinically,
a subacute loss of central vision develops in weeks/months,
mostly affecting young adult men, with a peculiar pattern of fiber
depletion8 and a relatively predictable natural history of visual
function decline.9 Exceptions apply to age of onset, with
childhood or late cases,10,11 to propensity in recovering vision,
more frequent with the m.14484 T4Cmutation,12 and to clinical
expression that in a subset of patientsmay bemorewidespread.4
The mtDNA mutations are necessary but not sufficient to
cause LHON,13 with penetrance being on average about 50%
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for males and 10% for females. The association of specific
mtDNA haplotypes of haplogroup J with the m.14484 T4C
and m.11778G4A mutations has been consistently docu-
mented in patients of European descent, indicating that
mtDNA background modulates to a certain extent disease
penetrance.14,15 However, in a prototypical LHON maternal
lineage, despite all the individuals carry the homoplasmic
mtDNA mutation regardless the haplogroup, only some
develop the disease, pointing to further factors that may be
genetic and environmental.16 Thus, male prevalence and
incomplete penetrance remain the two investigated and
problematic issues in LHON. Both issues have been recently
mechanistically related to the efficiency of compensatory
mitochondrial biogenesis.17,18 Estrogens ameliorate mito-
chondrial dysfunction by activating mitochondrial biogenesis,
suggesting that females are naturally protected during their
fertile period.17,19 Furthermore, by studying different experi-
mental systems (blood cells, skeletal muscle, skin-derived
fibroblasts and ocular tissue) we found that the unaffected
mutation carriers had a significantly higher mtDNA copy
number and mitochondrial mass compared with their affected
relatives,18 indicating that efficiently increasing mitochondrial
biogenesis may overcome the pathogenic effect of the mtDNA
mutation. Recently, others obtained similar results in different
LHON cohorts.20 Notwithstanding, nuclear modifiers remain
elusive. In particular, association of LHON with genetic
variants was not consistent across different studies.18,21
Similarly inconsistent was the association with chromosome
X-linked loci, hypothesized to explain male prevalence.22–24
Several other factors have been implicated in LHON,
including exposure to cigarette smoke, alcohol and chemical
toxins, head trauma, acute physical illness, psychological
stress, antiretroviral and antituberculosis drugs.4,25 These and
other environmental factors can have a triggering role in LHON
pathogenesis. For example, in vitro exposure to 2,5
exanedione had a toxic effect on LHON cybrid cells, with
an increased sensitivity if they harbored a haplogroup J
background.26 A major environmental trigger of LHON is
cigarette smoke; Sadun et al.27 and Kirkman et al.25 showed
that LHON penetrance is significantly increased in smokers,
independently of gender and alcohol intake.
In the current study, we explored further the effect of
cigarette smoking in LHON, showing in white blood cells from
patients of large LHON cohorts, and in skin-derived fibro-
blasts, that cigarette derivatives exert their toxicity by
depressing mtDNA copy number and oxidative phosphoryla-
tion (OXPHOS). However, unaffected mutation carriers
displayed the most efficient capacity for reactive oxygen
species (ROS) detoxification, which was not hampered by
exposure to cigarette derivatives.
Results
Tobacco smoking significantly depresses mtDNA copy
number in LHON patients. We previously studied the large
SOA-BR LHON family from Brazil and an Italian cohort of 39
LHON families demonstrating that a significant difference
characterizes unaffected mutation carriers compared with
affected individuals in terms of mtDNA copy number and
mitochondrial biogenesis, both of which are activated more
efficiently in unaffected mutation carriers.18 Having now
available mtDNA copy number and cigarette smoke habits
on the same subjects, we stratified the mtDNA quantitative
data by smokers/non-smokers in affected and unaffected
mutation carriers, considering separately the SOA-BR family
and the Italian cohort. A descriptive analysis reveals some
differences between the two cohorts. For example, all the
affected women in the SOA-BR cohort were non-smokers
(Figure 1a), whereas 20% of the affected women in the Italian
cohort were smokers (Figure 1b). Thus, to take into account
the composition of the two cohorts and their different genetic
background, we conducted a random-effects meta-regres-
sion, where both within-study and between-study variations
are considered.
In the first analysis, we estimated the differences in the
distribution of smokers between affected individuals and un-
affected mutation carriers. In both cohorts there was an in-
creased percentage of smokers in the affected group (Figure
1a and b) and the association result from the meta-analysis
was highly significant (P= 0.009; Supplementary Figure1A).
Subsequently, we analyzed the mtDNA copy number in the
carrier and affected groups, considering separately smokers
and non-smokers. As shown in Figure 1c and d, the affected
smokers had a lower mtDNA copy number as compared with
affected non-smokers and with the unaffected mutation car-
riers, with a similar tendency in both the Brazilian family
(Figure 1c) and the Italian cohort (Figure 1d). The unaffected
mutation carriers smokers displayed similar values as the non-
smokers. Pooling all the data for the affected individuals in a
meta-analysis, the reduction ofmtDNA copy number in affected
smokerswas significant (P=0.026; Supplementary Figure 1B).
Taken together, these results show that cigarette smoking
has a direct impact on LHON penetrance and that it may affect
the mtDNA copy number and the compensatory activation of
mitochondrial biogenesis, sparing the unaffected carriers.
Cigarette smoke condensate affects mtDNA copy num-
ber of fibroblasts. To directly test the effects of cigarette
smoking on LHON, we used fibroblasts derived from skin
biopsies of controls, LHON affected individuals and unaf-
fected mutation carriers. Cells were incubated with cigarette
smoke condensate (CSC), an extract that contains many
toxic compounds including polycyclic aromatic hydrocarbons
such as benzo-a-pyrene, phenolic compounds, tobacco-
specific nitrosoamine, aromatic amines, quinones and heavy
metals.28 We first analyzed fibroblasts viability after exposure
for 72 h to increasing amounts of CSC, finding that cell
viability, measured by the SRB cytotoxic assay, remained
unchanged up to a CSC concentration of 120 μg/ml, and then
declined in all cell categories (Supplementary Figure 2).
Therefore, in the subsequent experiments we chose to treat
cells for 72 h with amounts of CSC within 120 μg/ml, avoiding
higher concentrations for which CSC toxicity would affect cell
viability masking the potentially different response to cigarette
smoke of the three groups of cells.
To evaluate the effect of CSC on mtDNA copy number, we
extracted total DNA from cells incubated with 80 μg/ml of CSC
and measured the ratio between mtDNA and nuclear DNA by
qPCR. Figure 2a shows that exposure to CSC decreased the
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mtDNA copy number by about 25–30% in all three groups of
cells. This result confirms in vitro that tobacco toxicity induces
mtDNA copy number reduction.
Unaffected mutation carriers display the most efficient
compensatory activation of mitochondrial biogenesis
after exposure to CSC. Having established that exposure
to CSC leads to reduction of mtDNA copy number in
fibroblasts, we next investigated how CSC impacts on the
level of proteins marking mitochondrial mass and biogenesis
such as citrate synthase (CS), the subunit A of succinate
dehydrogenase (SDHA) and nuclear respiratory factor-1
(NRF-1). Figure 2b shows that exposure to 80 μg/ml of CSC
caused a significant increase in the level of all three proteins
in fibroblasts from unaffected mutation carriers, whereas
there was no significant variation in fibroblasts from controls
and affected individuals. We also measured the CS activity
and found that it exhibited the same trend of the protein
content (data not shown).
These results indicate that, despite the observed reduction
in mtDNA copy number, unaffected mutation carriers chal-
lenged by CSC can still orchestrate efficiently a compensatory
activation of mitochondrial biogenesis.
CSC exposure affects fibroblast bioenergetics. To study
the effect of CSC on bioenergetics, we assessed the rate of
ATP synthesis driven by Complex I substrates and oxygen
consumption of fibroblasts immediately after the addition of
incremental amounts of CSC. These treatments progres-
sively decreased ATP synthesis rate down to about 50% with
a slight prevalence in fibroblasts from LHON affected
individuals (Figure 3a). Similarly, the maximal respiration
capacity was decreased in all cell lines (Figure 3b), demon-
strating that CSC impacts on OXPHOS.
Figure 1 Mosaicplots and beanplots of the Brazilian SOA-BR family and Italian cohort of LHON families. (a and b) Mosaicplots of the relation between ‘Gender’, ‘Status’ and
‘Smoke’ in the Brazilian SOA-BR family and in the Italian cohort, respectively. Smokers are indicated with black rectangles and non-smokers in light gray. The areas of the boxes in
the plot are proportional to the cell frequencies of the contingency table for the three variables (c and d) Beanplots representing the distribution of mtDNA copies between smokers
(s) and non-smokers (ns) in the Brazilian SOA-BR family and in the Italian cohort, respectively. The short lines represent individual data points and the longest lines represent the
mean of the values
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We next measured the activities of respiratory Complexes I
and IV inmitochondria isolated from fibroblasts treated for 72 h
with 80 μg/ml of CSC. Figure 3c shows that Complex I activity
was markedly reduced in all three groups. Fibroblasts from
LHON affected subjects exhibited the strongest reduction (by
about 55%), whereas fibroblasts from unaffected mutation
carrier and controls were reduced by about 40%, with no
statistical differences among groups. Similarly, Complex IV
Figure 2 Effect of CSC on the fibroblasts mtDNA copy number and on the content of marker proteins of mitochondrial mass and biogenesis. Five samples for each cell type
were used and results are the average of quadruplicate determination for each sample. The histograms report the mean value (± S.E.M.) normalized to the untreated samples.
*P (treated versus untreated)o0.05. ***P (treated versus untreated)o0.001. (a) Effect of CSC on mtDNA copy number. Exposure to CSC decreases the level of mtDNA in all
three cell types (b) Effect of CSC on the content of CS, SDHA and NRF-1. CSC increases significantly the level of the three proteins only in carriers. No substantial change is
observed in affected and controls. A representative western blotting is also shown (UN, untreated; TR, treated)
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activity was reduced in carriers and affected by 57%, and
slightly less in controls by 47%. To evaluate the overall impact
of the OXPHOS impairment, we measured the total ATP
content in fibroblasts grown for 72 h in the presence of
incremental CSC amounts (from 20 to 120 μg/ml). ATP content
was not significantly impacted by CSC exposure in controls
(Figure 3d), whereas in both affected and unaffected mutation
carriers CSC decreased the ATP level by about 35%. Finally,
wemeasured the level of L-lactate excreted in the medium.We
found that the lactate level was slightly increased in both
affected and unaffected mutation carriers (Figure 3e). This
suggests that LHONmutant cells, notwithstanding pushing for
a greater energy metabolism by means of the glycolytic flux,
failed to reconstitute the ATP content.
Altogether these results clearly indicate that CSC affects
fibroblast bioenergetics, impacting mostly on the LHON
mutant cells.
CSC and ROS damage. Previous studies have demon-
strated that LHON cybrids have an increased ROS produc-
tion compared with controls.17,29 Moreover, LHON cybrids
have a reduced antioxidant defense that is highlighted by the
exposure to stressful condition such as growth in galactose
medium.30 Carbonyl groups of the proteins are a major
Figure 3 Effect of CSC on fibroblasts bioenergetics. (a) Rate of Complex I-dependent ATP synthesis. The values (mean± S.E.M.) are normalized to the respective untreated
samples (UN). Although not statistically significant, the data (average of measures done in three samples for each cell type) show that exposure to CSC decreases the rate of ATP
synthesis in all three cell types (b) Oxygen consumption rate (OCR) in adherent cells. The values, average percentage (± S.E.M.) of residual maximal respiration capacity with
respect to untreated cells (UN) show that CSC decreases the OCR in all three cell types with controls showing a slightly lower decrease. Each value was the mean based on at
least two independent determinations obtained from two different cell lines (c) Activity of respiratory Complex I and IV. Data are the average value (± S.E.M.) of three
determinations on four different samples for each cell type. The histogram shows the ratio of the complex activities between treated and untreated samples. *P (treated versus
untreated)o0.05. CSC treatment causes a decrease of the activities of both complexes. The decrease is slightly higher in the affected subjects (d) Intracellular level of ATP. The
values (average±S.E.M. of four measures done in five samples for each cell type) are normalized to the respective untreated samples (UN). *P (treated versus untreated)
o0.05; **Po0.01. Increasing amounts of CSC cause a significant decrease of ATP content in affected and carriers. No significant variation is observed for the control lines
(e) L-lactate level. The values (average±S.E.M. of four measures done in five samples for each cell type) are normalized to the respective untreated samples (UN). *P (treated
versus untreated)o0.05; **Po0.01. L-lactate increases significantly in affected and carriers at 80 μg/ml of CSC. Controls do not show a significant increase although they exhibit
an increasing trend
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product of a variety of ROS-mediated oxidation reactions, so
that their measurement provides a generalized and inte-
grated evaluation of the oxidative damage. As CSC is a
source of exogenous ROS, we first evaluated the effects of
ROS production in untreated fibroblasts from the three
groups (basal conditions) by measuring the amount of
carbonylated proteins. Figure 4 shows that carbonylated
proteins are more abundant in LHON affected fibroblasts than
in controls, thus confirming the previously observed increase
of ROS production in LHON cybrids.17,29–30 Interestingly,
fibroblasts from unaffected mutation carriers had the lowest
content of carbonylated proteins compared with both LHON
affected and also controls. This suggests that unaffected
mutation carriers display a more efficient antioxidant defense
compared with LHON affected individuals. Then, CSC
treatment increased the level of carbonylated proteins,
particularly in fibroblasts from LHON affected individuals (by
about 50%), whereas unaffected mutation carriers showed
only a moderate increase, and controls did not change
significantly (Figure 4). Considering that fibroblasts
from LHON affected individuals already had a higher ROS
damage compared with unaffected mutation carriers, the
CSC treatment further enhanced this difference.
CSC and ROS detoxification. To investigate how variable
levels of ROS damage relates to the efficiency of xenobiotic
detoxification pathways, we first assessed two nuclear
transcription factors involved in these processes, that is, the
aryl hydrocarbon receptor (AhR) and the Nuclear factor
erythroid 2-related factor 2 (Nrf2). AhR is a member of the
basic helix-loop-helix Per-Arnt-Sim transcription family and its
expression is essential to regulate cell proliferation and to
prevent mitochondrial dysfunction caused by cigarette
smoke.31 In particular, it has been shown that AhR regulates
the expression of manganese superoxide dismutase
(MnSOD). Nrf2 is a transcription factor that is activated by
oxidative stress and binds to the antioxidant response ele-
ments of target genes, including those involved in glutathione
synthesis, elimination of ROS, detoxification of xenobiotics
and drug transport.32 We measured the level of AhR and Nrf2
in basal conditions and found that both factors were higher in
unaffected mutation carriers than in LHON affected and
controls (Figure 5a). This result highlights that antioxidant
efficiency is greater in unaffected mutation carriers. CSC
treatment (80 μg/ml) only slightly modified this pattern increas-
ing the AhR level in the fibroblasts from affected individuals.
This indicates that in the presence of smoke derivatives LHON
mutant cells express the genes regulating xenobiotic detox-
ification at a higher level compared with controls.
We next measured the level of three cytosolic proteins
involved in ROS detoxification, such as NADPH dehydrogen-
ase quinone 1 (NQO1), glutathione S transferase mu5
(GST-M5) and glutathione reductase (GR). In basal conditions
the level of these proteins was slightly higher in unaffected
mutation carriers, compared with controls and LHON affected.
CSC treatment increased their levels in all cell types at a
similar extent (Figure 5b).
Finally, we evaluated the antioxidant response within
mitochondria, assessing the levels of MnSOD and peroxir-
edoxin III (Prx III). In basal conditions (Figure 5c) MnSOD was
highest in unaffected mutation carriers, reflecting the AhR
level. Prx III did not display significant variations among the
three cell types, being slightly lower in unaffected mutation
carriers and LHON affected compared with controls. CSC
treatment induced an increase of both proteins in all cell types,
with unaffected mutation carriers and controls exhibiting the
highest levels. The overall outcome of these studies is that
unaffected mutation carriers, previously shown to exhibit a
compensatory increase of mitochondrial biogenesis,18 also
display a more efficient system for ROS detoxification
compared with both LHON affected and control individuals.
Discussion
Previous epidemiological studies from our and other
laboratories25,27 suggested that cigarette smoke is signifi-
cantly associated with LHON penetrance. However, although
several reports indicated that cigarette smoke has various
deleterious effects onmitochondrial function33–36 its impact on
subjects carrying the LHON mutations has never been
previously investigated. Here, for the first time, we report
results that link directly the effects of cigarette smoke with
LHON penetrance. First, by crossing our pre-existing results
on mtDNA copy number with the information on cigarette
Figure 4 Effect of CSC on the level of carbonylated proteins. Five samples for
each cell type were used and experiments were performed in quadruplicate. All
values (average± S.E.M.) are normalized to the untreated control sample. A
representative western blotting is also shown (UN, untreated; TR, treated). *Po0.05;
***Po0.005. The histogram shows that in basal conditions the relative level of
carbonylated proteins is higher in the affected cells compared with the other cell
types. CSC treatment induces an increase of carbonylated proteins especially in
affected
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smoke exposure of the same subjects from two separate
LHON cohorts,18 we documented not only that tobacco smoke
was significantly associated with LHON affected individuals,
but also that among the affected individuals, smokers had
significantly reduced mtDNA copy number. Thus, tobacco
smoke further reduced the already limited efficiency of LHON
affected individuals to cope with the impaired respiratory
function. Then we studied the effect of cigarette extracts on
Figure 5 Effect of CSC on the level of proteins involved in ROS detoxification. Five samples for each cell type were used and experiments were performed in quadruplicate. All
values (average± S.E.M.) are normalized to the untreated control sample. A representative western blotting is also shown. *Po0.05. (a) Content of AhR and Nfr2. The histogram
shows that in the untreated samples both proteins have a higher level in carriers. CSC treatment induces a slight increase especially in the affected (b) Content of NQO1, GR
and GST-M5. The histogram shows that in the basal conditions carriers exhibit a higher level of the three proteins. CSC treatment causes a slight increase of the proteins in the
three cell types (c) Content of MnSOD and Prx III. In the untreated samples MnSOD is higher in carriers, while Prx III does not show significant variations among the three cell
types. CSC treatment increases the level of the two proteins especially in carriers and controls
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mtDNA copy number and other indexes of mitochondrial
biogenesis, bioenergetics and oxidative stress in fibroblasts
obtained from controls, LHON affected patients and unaf-
fected mutation carriers. We found that tobacco toxicity not
only reduces mtDNA copy number in all cell types, but also
directly affects mitochondrial function especially in mutant
cells. It remains unclear through which mechanism and
signaling pathway tobacco toxicity exerts its depressing effect
on mtDNA copy number. We consider this effect as additive to
the more direct and specific inhibition of single respiratory
complexes (I and IV), as we documented. Tobacco smoke-
induced reduction of respiratory complex activities has already
been shown in various systems, likely due to specific CSC
constituents.37–39 Unaffected mutation carriers were better
able to deal with tobacco toxicity by most efficiently activating
mitochondrial biogenesis. However, this was not sufficient to
compensate for the overall decline of mitochondrial bioener-
getics, as CSC exposure caused a decrease of the ATP
content in LHON mutant cells, including unaffected mutation
carriers, whereas in basal conditions carriers and controls had
a similar ATP content, higher than LHON affected.18
In spite of the diminished content of ATP specific to LHON
mutant cells, we found that respiratory enzyme activities and
oxygen consumption ratewere decreased in all cell types. This
may be due to a combination of different effects. The
unchanged ATP level in controls may be ascribed to a
‘threshold effect’. It is well-known that decrease in activity of
the respiratory complexes reflects on OXPHOS efficiency only
when it exceeds a certain threshold,40–41 which may vary
according to the experimental conditions and is usually high
(over 80% impairment in OXPHOS). Conversely, the decrease
of ATP content in the unaffected mutation carriers despite their
compensatory skills may be explained considering that
carriers, by exhibiting the highest ROS detoxifying activity
among the three groups of cells (see below), consume the
most ATP in xenobiotic solfatation and methylation reactions,
as well as in the synthesis of gluthatione.42–43 Furthermore,
the conversion of oxidized to reduced glutathione requires
NADPH, the reduced coenzyme is mainly provided by the
mitochondrial transhydrogenase activity that, is energy depen-
dent and driven by the electrochemical proton gradient.44
It has been shown in cybrids that LHON mutations increase
ROS production.17,29–30 However, the use of cybrids, in which
a uniform nuclear background derives from the original
osteosarcoma cell line,45 does not allow distinguishing
between unaffected mutation carriers and LHON affected.
We overcome this limit by using cultured fibroblasts, which
retain the different nuclear background. Our results show that
under basal conditions the levels of protein carbonylation in
fibroblasts from unaffected mutation carriers was significantly
lower compared with LHON affected and controls. Concor-
dantly, the level of several antioxidant enzymes was higher in
carriers compared with the other two cell types. Therefore,
carriers not only activate mitochondrial biogenesis better than
LHON affected individuals, but display also a better capability
to activate the antioxidant machinery. Even in the presence of
CSC, carriers exhibited the best compensatory response to
the increased oxidative stress compared with cells from LHON
affected individuals, displaying less carbonylated proteins and
higher level of several detoxifying enzymes.
The increased mitochondrial biogenesis and efficient ROS
protection displayed by carriers may depend on interlinked
pathways. Interestingly, several reports highlighted a relation-
ship between the Nrf2–NQO1 pathway and mitochondrial
biogenesis. Kwon et al.46 reported that loss of both proteins
decreased membrane potential and altered mitochondrial
integrity, whereas Piantadosi et al.47 showed that among the
genes activated by Nrf2 there is also NRF-1, which has a key
role as master regulator of mitochondrial biogenesis and is
increased in carriers treated with CSC. Therefore, Nrf2
activation could be a part of the signaling pathway leading to
efficient mitochondrial biogenesis. NQO1 is responsible for
using NAD(P)H as an electron donor to catalyze the 2-electron
reduction of damaging substances and quinones. The
formation of NAD+ has been recently shown to fuel mitochon-
drial biogenesis through Sirt1 and activation of PGC1ɑ.48–50
Therefore, the higher levels of proteins marking mitochondrial
mass and mitochondrial biogenesis (NRF-1 and SDHA),
Figure 5 Continued.
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exhibited by carriers in the presence of CSC, possibly depend
on a high efficiency of the Nrf2–NQO1 axis in these cells.
The efficient activation of mitochondrial biogenesis and ROS
protection pathways shown by LHONunaffected carriers ismost
probably due to differences in the nuclear genetic background
distinguishing them from the LHON affected individuals. The
genetic background, characterized by still unknown variants,
also interacts efficiently with environmental challenges, such as
exposure to tobacco toxicity. We recently found evidence51 that,
among individuals carrying the LHON mutations, some are
genetically primed to loose vision as young-adults in the
absence of any environmental exposure, whereas others
become affected with LHON only later, in mid-life, mostly
because of prolonged (decades) heavy exposure to environ-
mental triggers such as tobacco smoking. In this framework, the
here observed decline of ATP levels in carrier fibroblasts
exposed to CSC may be one of the effects of cigarette toxicity
prompting conversion from unaffected mutation carrier to LHON
affected. Thus, we believe that the genetic background priming
some individuals to be affected early in life differs from the
genetic background of individuals that become affected only
after prolonged exposure to heavy tobacco smoking and from
the genetic background that superprotects unaffected carriers
who never become affected, despite the exposure to tobacco
smoke. As a consequence, hunting for nuclear geneticmodifiers
must take into consideration not only covariates such as age
and sex, but most importantly, environmental exposure to
disease triggers. The results of association studies mixing
LHON affected individuals genetically primed to the disease by
nuclear genetic modifiers, with others affected only after an
overwhelming long exposure to cigarette smoke, are profoundly
biased by these confounding factors, diluting any meaningful
genetic signal. This is possibly the reason for the prolonged
failure to locate the LHON nuclear genetic modifiers.
In conclusion, the here reported results have a twofold
relevance for understanding LHON pathogenesis. First, the
major environmental trigger of LHON, tobacco smoking,
directly affects the compensatory mechanism counteracting
the pathogenic effects of LHON mutations, that is, the
homeostatic regulation of mitochondrial biogenesis and
maintenance of mtDNA copy number.18 The second important
inference from our study is that the effect of tobacco toxicity
clearly highlights how affected individuals are the less efficient
in compensating for the respiratory defect induced by the
LHON mutation, as opposed to unaffected mutation carriers,
who are the most efficient. These results integrate with the
previous studies by Giordano et al.,17 linking female estrogen
protection with compensatory activation of mitochondrial
biogenesis, which turns out to be a driving force for penetrance
in both genders.18 Overall, this study poses the basis to
correctly designing future investigations in the pursuit of
nuclear genetic modifiers implicated in LHON penetrance.
Materials and Methods
LHON Brazilian pedigree and Italian cohort of LHON families.
Blood samples and fibroblast cell lines were collected after informed consent according
to the Declaration of Helsinki Principles, and approval of the Ethics Committee of the
St. Orsola-Malpighi Polyclinic (University of Bologna) for the Italian cohort of LHON
families, and the Sao Paulo Hospital (Federal University of Sao Paulo) for the Brazilian
family SOA-BR. Both the Italian cohort and the SOA-BR family are the same reported
in ref 18, and information about environmental triggers, including tobacco and alcohol
consumption and toxic exposures, was obtained by telephone interviews and
structured questionnaires, following the same criteria as described previously.25 Overall,
we here investigated 25 affected and 38 unaffected mutation carriers from the maternal
line of the SOA-BR pedigree, and 64 affected and 68 carriers from 39 unrelated Italian
LHON pedigrees harboring one of the three common LHON mutations.18
CSC preparation. The CSC is a fraction that derives from the solid part of the
tobacco smoke and does not contain volatile components such as carbon
monoxide. It was prepared through a smoking machine CERULEAN SM 450, using
Coresta Monitor Test Pieces CM7 (Imperial Tobacco PLC, Hamburg, Germany). The
particulate matter was collected on a glass fiber filter and its mass was determined
by weighing the filter pad before and after the filtration. The particulate matter
was then dissolved in dimethylsulfoxide at a final concentration of 17.4 mg/ml. CSC
was stored at − 20 °C until used.
Fibroblasts cell lines and culture conditions. Fibroblast cell lines were
established from skin biopsies taken from five controls, seven affected (six
m.11778G4A and one m.14484 T4C) and six unaffected mutation carriers
(m.11778G4A). Cells were grown in DMEM medium (EuroClone, Milano, Italy)
containing 25 mM glucose and supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin, maintained at 37 °C in
a humidified atmosphere with 5% CO2. The functional experiments were carried out
on sub-confluent cell cultures obtained from a comparable number of culture
passages (10–20). CSC was added at the concentrations indicated in the Figures
and cells were kept for 72 h in the medium at 37 °C.
Detailed experimental procedures with cells (mitochondrial bioenergetics, SDS-
PAGE, western blotting and quantification of carbonylated proteins) are available in
the Supplementary Information.
Extraction of total DNA and evaluation of mtDNA in blood cells
and fibroblasts. Total DNA was extracted from an enriched white blood cell
fraction. Quantitative Real-Time PCR (qRT-PCR) was used to assess mtDNA
content in blood cells as reported in ref. 18.
Total fibroblast DNA was extracted using the Wizard Genomic DNA Purification Kit
(Promega, Madison Wisconsin, USA) following the manufacturer's instructions.
mtDNA copy-number quantification in fibroblasts was performed by a qRT-PCR
method based on TaqMan probe chemistry (Applied Biosystems, Life Technologies,
Monza, Italy), amplifying MT-ND1 and ACTB genes. Primer sequences and PCR
conditions are available upon request. The relative quantification of mtDNA was
performed according the Pfaffl mathematical model.52
Statistical analysis. Data were treated by analysis of variance with Tukey and
Tukey’s tests using SPSS Base 11.5 software (SPSS Inc., Chicago, IL, USA) to
assess the significance of the differences observed between groups. Statistical
significance was set at Po0.05 and indicated in the Figures reporting the data
analysis. Beanplots, Mosaicplots and Forestplots were generated using R ver. 3.1.3
(software freely available at the website https://www.r-project.org/). The meta-analysis
was conducted using R and the package metafor ver. 1.9–5 (freely available at the
website http://www.metafor-project.org/doku.php) adopting the method of restricted
maximum-likelihood estimator and a random-effect meta-regression model.
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